Wren Capital

Monument Therapeutics is a biotechnology company focused on developing innovative drugs for serious diseases affecting the central nervous system. The company employs proprietary digital biomarkers to enhance patient identification by reducing heterogeneity and targeting those with similar underlying neurobiological conditions. This approach allows researchers to concentrate on advancing treatments in areas with significant unmet medical needs within the field of neuroscience.

Spotta Ltd is a company that specializes in developing smart pest control systems aimed at the hotel and lodging industry, focusing on the early detection of bed bugs. Founded in 2018 and headquartered in Cambridge, United Kingdom, Spotta offers a battery-powered insect monitoring sensor that alerts users to potential bed bug infestations. This innovative technology analyzes detection data to ensure that notifications pertain only to genuine incidents, allowing hotels to proactively prevent bed bugs from spreading and facilitating more efficient and cost-effective treatment options. By leveraging these systems, lodging providers can enhance guest satisfaction and maintain a pest-free environment.

MitoRx Therapeutics is a biotechnology company that focuses on developing innovative therapeutics aimed at reversing mitochondrial dysfunction. The company targets various conditions, including neuromuscular disorders, metabolic diseases, and dementia. By specializing in mitochondrial-protective therapies, MitoRx seeks to address the underlying causes of these challenging diseases. The company is committed to both developing treatments for rare indications and forming partnerships to tackle broader health issues. Through its efforts, MitoRx aims to enable healthcare professionals to halt the progression of conditions associated with dystrophy and neurodegeneration.

Bastion Therapeutics is a preclinical stage biotechnology startup focused on developing innovative anti-inflammatory cell therapies. The company utilizes proprietary platform technology to enhance regulatory T cells (Tregs) within the immune system. By targeting neuroinflammation in the central nervous system, Bastion's therapies aim to protect neurons and improve synaptic connectivity. This approach seeks to help patients maintain cognitive function and prevent its decline, addressing significant challenges in neurodegenerative conditions.

PharmEnable Limited is a drug discovery company based in Cambridge, United Kingdom, that was incorporated in 2016. The company specializes in using medicinal chemistry and artificial intelligence to design small molecule drugs. PharmEnable has developed a rapid and cost-effective method for identifying improved chemical starting points, which aims to enhance the discovery of essential new medicines.

MitoRx Therapeutics is a biotechnology company that focuses on developing innovative therapeutics aimed at reversing mitochondrial dysfunction. The company targets various conditions, including neuromuscular disorders, metabolic diseases, and dementia. By specializing in mitochondrial-protective therapies, MitoRx seeks to address the underlying causes of these challenging diseases. The company is committed to both developing treatments for rare indications and forming partnerships to tackle broader health issues. Through its efforts, MitoRx aims to enable healthcare professionals to halt the progression of conditions associated with dystrophy and neurodegeneration.

AdaptTech is a biomedical company based in Birmingham, United Kingdom, that specializes in developing innovative wearable technologies aimed at enhancing the quality of life for individuals with physical disabilities. Founded in 2015, the company offers a range of products designed to assist clinicians in achieving better socket fitting and monitoring for patients who have lost a lower limb. Key offerings include the INSIGHT Scanner, which quickly creates a three-dimensional model of prosthetic sockets, the INSIGHT Wearable that collects real-time biometric data, and the INSIGHT App that provides users with easy access to their results. Through these advancements, AdaptTech seeks to improve the overall experience and outcomes for those relying on lower limb prosthetics.

Centauri Therapeutics is a biotechnology company focused on the discovery and development of innovative immunotherapeutics aimed at addressing life-threatening diseases. Utilizing its proprietary Alphamer technology, Centauri creates chemically synthesized molecules that redirect naturally occurring antibodies to specific pathogens, enhancing the body's immune response. The company's dual-action approach involves directly targeting cell surface antigens while employing a glycan effector domain to stimulate a robust polyclonal immune response. This mechanism promotes cell death via enhanced complement fixation, antibody-dependent cellular cytotoxicity, and phagocytosis by myeloid cells. Centauri has demonstrated strong pre-clinical results, showcasing significant improvements in complement fixation and opsonophagocytosis for both anti-bacterial and oncology therapeutics, as well as in vivo proof-of-concept data across various infection models.

Tay Therapeutics is a biotechnology company focused on drug discovery, specifically developing innovative topical and oral therapies for inflammatory skin conditions. The company aims to create alternatives to commonly prescribed steroid creams used for treating diseases like psoriasis and eczema. These steroid treatments can often be ineffective and may lead to significant side effects. By prioritizing the safety and efficacy of their medications, Tay Therapeutics seeks to provide patients with better treatment options for managing their skin diseases.

Monument Therapeutics is a biotechnology company focused on developing innovative drugs for serious diseases affecting the central nervous system. The company employs proprietary digital biomarkers to enhance patient identification by reducing heterogeneity and targeting those with similar underlying neurobiological conditions. This approach allows researchers to concentrate on advancing treatments in areas with significant unmet medical needs within the field of neuroscience.

AdaptTech is a biomedical company based in Birmingham, United Kingdom, that specializes in developing innovative wearable technologies aimed at enhancing the quality of life for individuals with physical disabilities. Founded in 2015, the company offers a range of products designed to assist clinicians in achieving better socket fitting and monitoring for patients who have lost a lower limb. Key offerings include the INSIGHT Scanner, which quickly creates a three-dimensional model of prosthetic sockets, the INSIGHT Wearable that collects real-time biometric data, and the INSIGHT App that provides users with easy access to their results. Through these advancements, AdaptTech seeks to improve the overall experience and outcomes for those relying on lower limb prosthetics.

Antiverse is an innovative antibody discovery company that aims to accelerate drug development through its advanced platform. By integrating structural biology, machine learning, and medicine, Antiverse provides solutions to predict antibody-antigen binding and identify potential antibody drug candidates for challenging targets. The company employs machine learning and cell-free protein synthesis to enhance the prediction of antibody affinity for specific antigen targets, allowing pharmaceutical companies and contract research organizations to expedite the antibody hit discovery process. Antiverse is committed to transforming drug development and improving patient outcomes.

Tay Therapeutics is a biotechnology company focused on drug discovery, specifically developing innovative topical and oral therapies for inflammatory skin conditions. The company aims to create alternatives to commonly prescribed steroid creams used for treating diseases like psoriasis and eczema. These steroid treatments can often be ineffective and may lead to significant side effects. By prioritizing the safety and efficacy of their medications, Tay Therapeutics seeks to provide patients with better treatment options for managing their skin diseases.

Spotta Ltd is a company that specializes in developing smart pest control systems aimed at the hotel and lodging industry, focusing on the early detection of bed bugs. Founded in 2018 and headquartered in Cambridge, United Kingdom, Spotta offers a battery-powered insect monitoring sensor that alerts users to potential bed bug infestations. This innovative technology analyzes detection data to ensure that notifications pertain only to genuine incidents, allowing hotels to proactively prevent bed bugs from spreading and facilitating more efficient and cost-effective treatment options. By leveraging these systems, lodging providers can enhance guest satisfaction and maintain a pest-free environment.

Sarissa Biomedical, Ltd. specializes in the development and production of innovative biosensors aimed at measuring neuroactive chemicals for research and clinical diagnostic purposes. The company focuses on creating minimally invasive, microelectrode electrochemical sensors that accurately measure purines and other neurochemicals, serving as indicators of neurological activity and disorders. These biosensors are suitable for both in vitro and in vivo studies. Additionally, Sarissa Biomedical is developing a hand-held point-of-care diagnostic device that utilizes finger-prick blood samples to identify individuals experiencing strokes. Founded in 2002 and based in Coventry, the United Kingdom, Sarissa Biomedical markets its products in various regions, including the United Kingdom, United States, Canada, and Japan.

Procarta Biosystems Ltd, founded in 2007 and based in Norwich, United Kingdom, develops innovative antibacterial therapies using a DNA-based platform. The company focuses on addressing the growing challenge of drug-resistant bacterial strains by offering a range of proprietary nanoparticles, collectively referred to as "snare." These nanoparticles facilitate the delivery of oligonucleotides targeting various bacterial pathogens, including MRSA, through both topical and intravenous solutions. Additionally, Procarta's therapies include a broad-spectrum treatment for Gram-negative infections, particularly those acquired in hospital settings, and a specific solution aimed at preventing the recurrence of Clostridium difficile infections. Originating as a spin-out from the John Innes Centre, Procarta has garnered early-stage investment and operates within the Norwich Research Park, contributing to advancements in antibiotic development for challenging infections.

Oxford Space Systems Limited, founded in 2013 and based in Harwell, United Kingdom, specializes in the development, manufacture, and marketing of deployable hardware structures for space environments. The company focuses on creating innovative deployable antennas, panels, hinge systems, and composite linear boom systems, utilizing advanced design techniques such as origami and proprietary materials. These technologies aim to produce structures that are lighter, less complex, and more cost-effective than traditional alternatives, catering to the global satellite industry. Oxford Space Systems has gained recognition for its rapid product development, notably with its AstroTube Boom, which achieved successful deployment in under 30 months. The company has engaged in various co-development projects supported by the UK government, collaborating with leading European satellite manufacturers and securing commercial contracts in Asia and the US. With a growing team of professionals possessing extensive experience in the space sector, Oxford Space Systems operates from a custom facility at the Harwell Space Cluster, equipped to handle defense and security contracts.

PredictImmune Ltd is a biotechnology company based in Cambridge, United Kingdom, focused on developing prognostic tests for immune-mediated inflammatory diseases. The company's flagship product, PredictSURE IBD, is a diagnostic tool that evaluates patients with inflammatory bowel disease, including Crohn's disease and ulcerative colitis. This test utilizes a small blood sample to identify patients at diagnosis who are at risk of severe, relapsing disease, thereby enabling healthcare providers to recommend early biologic therapy to those who would benefit most. By providing crucial prognostic information, PredictImmune aims to enhance treatment decision-making for physicians and improve outcomes for patients suffering from these conditions. The company's research is rooted in leading studies from Cambridge University, reflecting its commitment to advancing personalized medicine in the field of inflammatory bowel disease.

Smartpipe is creating the only global, real-time, privacy compliant and completely secure data ecosystem for the monetisation of network operators’ rich customer data. Their patent-protected solution enables network operators, data providers, advertising agencies and brands to mutually benefit from high-quality, privacy compliant data assets, driving ROI for the entire data monetisation value chain. Made possible by a single technical integration into multiple ecosystems such as advertising, e-commerce and financial services, Smartpipe’s approach offers contextual, consented and anonymised customer data segments to data partners in real-time. This enables the delivery of highly relevant and targeted commercial communications to consumers. Smartpipe is backed by leading mobile, enterprise and SaaS investors, is headquartered in London with a software and development research centre in Cwmbran.

Keit Ltd. specializes in the design and manufacture of advanced spectrometers and related instruments that operate across a spectrum from ultraviolet to far infrared rays. Established in 2012 and based in Didcot, United Kingdom, the company focuses on innovative applications for its products, which include the measurement of signal levels, vibrations, and various substances in both gas and liquid forms. One of Keit's flagship products is the microFTS®, a compact and rugged Fourier Transform Infrared (FTIR) spectrometer originally developed for space applications. This device sets a new benchmark for real-time liquid-state analyses and serves industries such as pharmaceuticals, chemicals, oil and gas, and food and beverage, where performance in extreme environments is crucial.

Spectral Edge Ltd, established in 2011 and headquartered in Cambridge, UK, specializes in image enhancement technologies. The company develops innovative solutions such as Phusion, which improves image and video quality by leveraging information outside the visible spectrum, and Eyeteq, a video personalization technology that enhances TV accessibility for color-blind individuals. Spectral Edge's products cater to consumer electronics manufacturers and service providers, serving applications like computational photography, security, and consumer electronics. As of 2019, the company operates as a subsidiary of Apple Inc.

Oxford Space Systems Limited, founded in 2013 and based in Harwell, United Kingdom, specializes in the development, manufacture, and marketing of deployable hardware structures for space environments. The company focuses on creating innovative deployable antennas, panels, hinge systems, and composite linear boom systems, utilizing advanced design techniques such as origami and proprietary materials. These technologies aim to produce structures that are lighter, less complex, and more cost-effective than traditional alternatives, catering to the global satellite industry. Oxford Space Systems has gained recognition for its rapid product development, notably with its AstroTube Boom, which achieved successful deployment in under 30 months. The company has engaged in various co-development projects supported by the UK government, collaborating with leading European satellite manufacturers and securing commercial contracts in Asia and the US. With a growing team of professionals possessing extensive experience in the space sector, Oxford Space Systems operates from a custom facility at the Harwell Space Cluster, equipped to handle defense and security contracts.

Monica Healthcare specializes in the manufacturing and supply of advanced fetal monitoring devices aimed at improving obstetric care for midwives, labor and delivery nurses, and expectant mothers. The company’s flagship product, The Novii, is a single-use wireless patch system that monitors maternal heart rate, fetal heart rate, and uterine activity, enhancing the birthing experience. Additionally, Monica Healthcare develops a range of wearable devices that utilize innovative wireless technologies to provide accessible obstetric services both in hospitals and at home. The company also offers training, repairs, and support services for its products. Established in 2005 and headquartered in Nottingham, United Kingdom, with a location in Kennesaw, Georgia, Monica Healthcare operates as a subsidiary of GE Healthcare.

Cytox Limited specializes in developing products and services aimed at diagnosing and treating neurodegenerative disorders, particularly Alzheimer's disease. The company has created a genetic-based blood test that assesses the risk and diagnosis of Alzheimer's in its early stages, addressing a critical need as the prevalence of the disease rises globally. Cytox's offerings include cellular and genetic assays for identifying cell cycle deficits in patients, along with biomarker and drug-screening services for pharmaceutical companies engaged in clinical trials. The company collaborates with Affymetrix, part of Thermo Fisher Scientific, to enhance its commercial testing capabilities. Founded in 2004 and headquartered in Birmingham, United Kingdom, with additional offices in Manchester and Oxford, Cytox serves pharmaceutical and biotechnology firms, as well as research laboratories involved in clinical research and drug development.

Momentum Bioscience Ltd is a biotechnology company specializing in the development of rapid diagnostic tests for critical clinical specimens. Established in 2005 and based in Cardiff, United Kingdom, the company utilizes its innovative Enzyme Mediated Amplification (EMA) technology to enable the universal detection of viable bacteria and fungi in under two hours, significantly reducing the time compared to traditional laboratory methods that can take 1 to 5 days. Momentum Bioscience's products are particularly valuable in neonatal care, emergency care, and critical care settings, as they specifically measure viable organisms, ensuring accurate detection of infections in blood and other normally sterile body fluids. The company is focused on advancing its suite of related technologies to enhance pathogen detection and support microbiology laboratories.

Captive Media Ltd is a British company that specializes in developing and managing an interactive entertainment system designed for washrooms, particularly targeting male users. The company offers a patented urinal-mounted gaming console that features networked digital video screens displaying a mix of engaging content and advertisements. The system utilizes infra-red sensors to detect a user's stream, allowing them to control interactive games without physical contact with the screen. Games include activities such as trivia quizzes, slalom skiing, and racing, designed to capitalize on the average dwell time of 55 seconds at urinals. The units are retrofitted into existing washroom facilities and require only power and internet connections, making them suitable for installation in bars, clubs, hotels, sports venues, and shopping malls throughout the UK and EU. Captive Media also collaborates with brands and agencies to promote responsible drinking and branded products through its innovative advertising platform, which is reinforced to an industrial grade and is both waterproof and vandal-proof.

Blu Wireless Technology is a Silicon IP company specializing in the development of 60GHz baseband technology aimed at enhancing WiGig and 4G backhaul applications. The company focuses on creating high-bandwidth communication systems tailored for the telecom and semiconductor markets, enabling clients to efficiently establish 5G infrastructure. Blu Wireless offers its technology as a complete System IP solution, capable of delivering data rates exceeding multiple Gbps over distances greater than 300 meters. With expertise in mmWave silicon IP and a deep understanding of market demands, Blu Wireless provides partners and customers with reliable solutions that stand out in a competitive landscape while remaining cost-effective and timely.

Horizon Discovery Group plc is a UK-based life science company specializing in gene editing and gene modulation technologies that advance research and clinical applications in human health. Established in 2007 and headquartered in Cambridge, the company designs, manufactures, and applies a wide array of gene editing tools, including custom-made and off-the-shelf RNA interference (RNAi) reagents, CRISPR reagents, and various cell models. Horizon Discovery offers services such as pooled and arrayed CRISPR screens, drug screens, and immunology assays, catering to the needs of academic research labs, biopharmaceutical companies, and contract research organizations. Its extensive product catalog includes over 1,000,000 cell and reagent products that help scientists investigate genetic anomalies associated with diseases like cancer. The company has formed strategic partnerships with various institutions to enhance its offerings, including collaborations for developing innovative gene editing technologies. As of December 2020, Horizon operates as a subsidiary of PerkinElmer (UK) Holdings Ltd.

Cytox Limited specializes in developing products and services aimed at diagnosing and treating neurodegenerative disorders, particularly Alzheimer's disease. The company has created a genetic-based blood test that assesses the risk and diagnosis of Alzheimer's in its early stages, addressing a critical need as the prevalence of the disease rises globally. Cytox's offerings include cellular and genetic assays for identifying cell cycle deficits in patients, along with biomarker and drug-screening services for pharmaceutical companies engaged in clinical trials. The company collaborates with Affymetrix, part of Thermo Fisher Scientific, to enhance its commercial testing capabilities. Founded in 2004 and headquartered in Birmingham, United Kingdom, with additional offices in Manchester and Oxford, Cytox serves pharmaceutical and biotechnology firms, as well as research laboratories involved in clinical research and drug development.

LumeJet Print Technologies Limited is a company based in Coventry, United Kingdom, that specializes in the design, development, and manufacture of ultra-high resolution printers tailored for production environments. These printers are utilized for various applications, including layflat books, fine art prints, pitches and proposals, book jackets, and wedding albums. Additionally, LumeJet's technology supports inkless printing for labeling and packaging, printed electronics, and direct-write digital lithography for photomasking on printed circuit boards and flexible substrates. The company distributes its products through a network across Europe and North America. Established in 2009, LumeJet was previously known as LumeJet Limited before rebranding in September 2015.

Specle Limited is a company that provides a centralized data platform for validated production and media information, primarily in the United Kingdom and Belgium. Founded in 2006 and based in London, Specle serves pre-media providers, publishers, and media agencies by offering a production tool that helps advertising agencies and pre-press providers prepare final advertisements according to publisher specifications. The platform hosts validated advertising specifications for thousands of publications across the UK and Europe, allowing advertisers and creative agencies to access the exact technical requirements for print, digital out-of-home, and digital editions. Specle's services enable users to upload, validate, and deliver advertisements directly to publishers, sometimes integrating them into the publication's flat plan. Known for its user-friendly technology, Specle caters to both one-time advertisers and large brands that require high-volume ad delivery, emphasizing customer support and tailored solutions for its clients.